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Introduction {#sec1}
============

Dendritic cells (DCs) are specialized antigen-presenting cells (APCs) that link innate to adaptive immunity ([@bib67]). Upon encounter with pathogens, they get activated resulting in maturation and migration to draining lymph nodes. Primed DCs then polarize naive and memory T helper (Th) cells into various effector subtypes such as Th1, Th2, Th17, or Tregs ([@bib25], [@bib29]). The differentiation of these different Th subsets depends on the DC maturation status and the secreted cytokines. DCs are thus considered as major players in fine-tuning immunity versus immune tolerance.

DCs express a range of pattern recognition receptors such as Toll-like receptors (TLRs) to identify a wide plethora of pathogens ([@bib69]). Here in this study, we have focused mostly on CD8^+^ cDC1 DCs. cDC1 DCs are the main antigen cross-presenting DCs for intracellular pathogens detected through TLR3 and TLR9 ([@bib58], [@bib61]). Upon ligation of these receptors, Myd88 and TRIF signaling pathways are stimulated, consequently activating transcription factors (TFs) like nuclear factor (NF)-κB and interferon regulatory factors (IRFs) and a variety of protein kinases ([@bib30], [@bib51]). It has been reported that in DCs canonical NF-κB signaling through IkBα activates both RelA and RelB, whereas in other cells like fibroblasts only non-canonical signaling results in RelB activation ([@bib64]). RelA signaling is important for pro-inflammatory response and cell survival ([@bib64]). On the other side, RelB is reported to be involved in DC maturation and induction of tolerance ([@bib6], [@bib71]). Therefore depending on the stimulus and a fine balance of NF-κB activity, DCs exhibit either immunogenic or regulatory phenotype ([@bib75]). The activation stimulus results in signal-specific expression of a large number of DC response genes including cytokines (interleukin \[IL\]-6, IL-10, IL-12) and co-stimulatory markers (CD40, CD80, and CD86) ([@bib42]). Depending on the strength and specificity of these DC responses, naive Th cells differentiate into different effector subtypes ([@bib25], [@bib28]). The inflammatory cytokine IL-12 with strong co-stimulatory signals results in Th1, whereas anti-inflammatory signals IL-4, IL-5, and IL-13 induce Th2 development ([@bib38]) ([@bib40]). Similarly, the cytokine IL-10, with strong or weak co-stimulatory signals, respectively, generates Th2 or Tregs ([@bib16], [@bib59]). Thus, it has been widely proposed that DC responses can be modulated to treat a variety of diseases, such as cancer and autoimmunity ([@bib45]).

We know that DCs receive multiple stimulatory cues to generate signal-specific responses, and it appears improbable that TFs alone can integrate such a vast number of regulatory signals. One of the well-characterized mechanisms how nuclear receptors (NRs) regulate transcriptional responses is through the recruitment of transcriptional co-regulators (co-repressors or co-activators) ([@bib43], [@bib47], [@bib49]). Recent reports show that DC treatment with high-affinity NR ligands such as rosiglitazone and vitamin D modulates expression of co-stimulatory molecules and cytokine genes, which perturbs their functional responses ([@bib1], [@bib18], [@bib72]). Analysis of published NCoR1 chromatin sequencing (ChIP-seq) data from macrophages revealed NCoR1 binding on genes accountable for antigen recognition, co-stimulation, and T cell polarization in DCs. This strongly suggested the functional involvement of NR co-repressors like NCoR1 in DCs, as they were identified in complexes with unliganded NRs such as peroxisome proliferator activated receptor gamma (PPARγ) and thyroid receptor (TR) ([@bib13], [@bib27], [@bib36], [@bib46], [@bib85]). These co-repressors inhibit gene expression through chromatin compaction by recruiting histone deacetylases ([@bib27], [@bib52]). In contrast, we reported NCoR1 enrichment at open chromatin regions marked by H3K27ac/H3K4me1 ([@bib56]). Despite several reports indicating so, a role of NCoR1 in DC function has not been directly evaluated in a systematic study.

Here, we employed an immunogenomics approach to elucidate the role of NCoR1 in DC function. We demonstrated NCoR1 as a master regulator of the tolerogenic program in cDCs. We found that direct repression of tolerogenic genes by NCoR1 upon DC activation is important to induce an optimal immunogenic response. In addition, we explored the underlying molecular mechanisms and *in vivo* physiological impact of NCoR1-modulated DC responses in parasite-infected animals.

Results {#sec2}
=======

NCoR1 KD cDC Line Showed Enhanced Tolerogenic Responses upon Activation {#sec2.1}
-----------------------------------------------------------------------

To determine the role of NCoR1 in DCs, we have developed a stable NCoR1 knockdown (KD) and matched empty vector-transduced control cells using lentiviral short hairpin RNA (shRNA) approach in a CD8α^+^ cDC1 DC line that mimics remarkably the *ex vivo* isolated cDC1 DCs ([@bib21], [@bib66]). We found that NCoR1 transcript levels were significantly reduced (≥85%) in NCoR1 shRNA-transduced DCs ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}A). We first performed qPCR-based immune profiling of control and NCoR1 KD DCs. We found that NCoR1 depletion significantly increased transcripts of several immune-modulatory genes including *Il-10, Il-12p40, Il-27, Ido1,* and *Pdl1* upon 2-, 6-, and 12-h CpG challenge ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc2){ref-type="supplementary-material"}A). The luminex assay showed significantly increased secretion of IL-2, IL-6, and IL-10 cytokines in the culture supernatants of 6-h CpG-activated NCoR1 KD DCs, whereas the IL-12 cytokine was insignificantly increased ([Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc2){ref-type="supplementary-material"}B). The median fluorescence intensity (MFI) shifts showed a significant decrease of CD80 in unstimulated conditions, whereas upon CpG activation CD80, CD86, major histocompatibility complex (MHC)-I, and PDL1 expression were significantly increased ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}C). CD40 and MHC-II remain unchanged in both the conditions ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}C). Moreover, the intracellular expression of IL-6, IL-10, IDO1, and IL-27 cytokines showed significantly increased levels in 6-h CpG-challenged NCoR1 KD DCs, whereas IL-12p40 showed an insignificant increase ([Figures 1](#fig1){ref-type="fig"}D and [S1](#mmc1){ref-type="supplementary-material"}D). The expression of *IL-10* is predominantly dependent on Erk kinase activity ([@bib59]). We found significantly increased pErk^+^IL-10^+^pSTAT3^-^ cells in activated NCoR1 KD DCs ([Figure S1](#mmc1){ref-type="supplementary-material"}E).Figure 1NCoR1 KD Enhances Tolerogenic Responses in Conventional DCs upon CpG Challenge(A) Bar plot depicting the transcript expression of selected immunogenic and tolerogenic response genes in 6 h CpG-stimulated NCoR1 KD cDC1 DCs relative to control cells as quantified by qPCR (n = 3).(B) Bio-Plex quantitation of the secreted cytokines IL-2 and IL-10 in the culture supernatants of 6 h CpG-challenged NCoR1 KD and control DCs (n = 6).(C) Graph demonstrating the MFI for DC activation and co-stimulation markers CD80, CD86, MHC-II, and PDL1 in NCoR1 KD and control cDC1 DCs before and after 6 h CpG challenge. Corresponding histogram plot is a representative plot for MFI shifts observed for respective markers (n = 4--8).(D) Scatterplot showing the percentage positive cells for intracellular expression of IL-10, IDO1, and IL-27 in 0 h and 6 h CpG-stimulated NCoR1 KD and control cDC1 line. Corresponding bar plot and histogram show the MFI shifts observed for the respective genes (n = 4).p values are calculated using two-tailed paired Student\'s t test; error bars represent SEM. \*p ≤ 0.05, \*\*p ≤ 0.01, \*\*\*p ≤ 0.001. See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

Moreover, we also developed a stable NCoR1 KD CD11b^+^ cDC2 DC line ([@bib53]). Similar to cDC1 DCs, we identified a significantly increased percentage of positive cells for IL-10, IL-27, PDL1, IL-6, and IL-12p40 cytokines after CpG activation in NCoR1-depleted DCs ([Figure S1](#mmc1){ref-type="supplementary-material"}F). Lipopolysaccharide challenge showed similar trends ([Figure S1](#mmc1){ref-type="supplementary-material"}F).

At the same time, to identify if any strong stimulation renders similar responses in NCoR1-depleted cDCs, we challenged NCoR1 KD and matched control cDC1 DCs with pIC (TLR3) and CpG + pIC (TLR3 and TLR9 together) simultaneously. We found that NCoR1 depletion enhanced expression of IL-10, IL-27, IDO-1, and PDL1 along with IL-6 and IL-12p40 in cDC1 DC line with both these stimulations ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Moreover, simultaneous activation showed stronger DC responses ([Figure S2](#mmc1){ref-type="supplementary-material"}A). We also challenged NCoR1 KD and control CD8α^+^cDC1 DCs with gram-positive (*Mycobacterium smegmatis, B. subtilis* and *Staphylococcus aureus*), and gram-negative (*Vibrio cholerae, Shigella dysenteriae,* and *Salmonella typhimurium*) bacteria. Interestingly, we found a profound increase of IL-10, IL-27, IDO1, CTLA4, and PDL1 in NCoR1 KD DCs in all these stimulations ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C).

Indoleamine 2,3-dioxygenase (IDO) enzyme metabolizes L-tryptophan to L-kynurenine resulting in the inhibition of effector Th cell differentiation ([@bib80]). We found a significantly increased IDO activity in the culture supernatants of NCoR1 KD DCs when compared with controls ([Figure S1](#mmc1){ref-type="supplementary-material"}G). This further substantiated our observation that NCoR1 directly controls the tolerogenic program in cDCs upon activation. Several recent reports showed an enhanced expression of IL-10 along with PDL1, IL-27, and IDO1 in tolerogenic DCs ([@bib33], [@bib44], [@bib74], [@bib83]). Collectively, we demonstrated that NCoR1 depletion induces strong tolerogenic response upon activation in cDCs.

NCoR1 KD cDC1 DCs Increased Frequency of Treg Development *Ex Vivo* {#sec2.2}
-------------------------------------------------------------------

To access the impact of NCoR1 depletion in cDCs on Th cell differentiation, we co-cultured NCoR1 KD and control cDC1 DCs with naive CD4^+^ Th cells isolated from OT-II mice ([Figure 2](#fig2){ref-type="fig"}A). We found profoundly increased proliferation of Th cells co-cultured with CpG-pulsed NCoR1 KD DCs when compared with control cells ([Figure 2](#fig2){ref-type="fig"}B). In addition, the differentiation profile showed a significantly higher number of CD25^+^FoxP3^+^ Tregs in NCoR1-depleted conditions ([Figure 2](#fig2){ref-type="fig"}C). Tbet and interferon (IFN)-γ-positive cells were significantly reduced, whereas GATA3 showed an increasing trend ([Figure 2](#fig2){ref-type="fig"}D) The MFI shifts showed similar trends ([Figure 2](#fig2){ref-type="fig"}C). In unstimulated conditions, no changes were observed ([Figure 2](#fig2){ref-type="fig"}D). These results confirmed the tolerogenic potential of activated NCoR1 KD cDC1 DCs.Figure 2NCoR1 Depletion Enhances Differentiation of Naive CD4^+^ Th Cells into Tregs(A) Experimental outline used to assess the effects of NCoR1 KD on T cell polarization *ex vivo*.(B) Representative histograms showing the MFI shifts observed for proliferation of T helper cells co-cultured with unstimulated or CpG-activated NCoR1 KD and control cDC1 DCs (n = 3).(C) Histogram plots demonstrating the representative MFI shifts observed for FoxP3, Tbet, IFNγ, and GATA3 in helper T cells co-cultured with NCoR1 KD and control cDC1 DCs for 5 days (n = 5).(D) Scatterplots from flow cytometric analysis showing the percentage positive T helper cells expressing CD25^+^FoxP3^+^, Tbet, IFNγ, and GATA3 after 5 days of co-culture with activated NCoR1 KD and control DCs (n = 5).p values are calculated using two-sample unpaired Student\'s t test; error bars represent SEM. \*p ≤ 0.05, \*\*\*p ≤ 0.001.

Conventional DCs from NCoR1^DC-/-^ Mice Showed Increased Tolerogenic Responses upon CpG Challenge {#sec2.3}
-------------------------------------------------------------------------------------------------

To validate the findings *in vivo*, we developed DC-specific conditional NCoR1 knockout mice by crossing CD11c-Cre strains with floxed NCoR1 mice ([@bib79]). Genotyping PCR confirmed NCoR1 ablation in CD11c^+^ cDCs ([Figure S3](#mmc1){ref-type="supplementary-material"}A). To obtain sufficient numbers of DCs *ex vivo* from NCoR1^DC−/-^ and wild-type (WT) mice, we treated them with serum from FLT3L transgenic mice (equivalent to 50 μg FLT3L/mouse/day) for eight consecutive days ([@bib7]). First, we profiled DC subtype composition (cDCs and pDCs) after FLT3L treatment. We found that the frequencies of CD8^+^ (cDC1) and CD11b^+^ cDCs (cDC2) were profoundly increased in FLT3L-treated mice ([Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C). Then, splenocytes from NCoR1^DC−/-^ and WT mice were stimulated for 6 h with or without CpG and analyzed by fluorescence-activated cell sorting (FACS) to identify the impact of NCoR1 ablation on different subsets of primary CD11c^+^ cDCs ([Figure S3](#mmc1){ref-type="supplementary-material"}D). We found that NCoR1 loss in CD11c^high^CD8^+^ cDC1 DCs significantly enhanced the percentage positive cells of IL-10, IL-27, and IDO1 after activation, whereas IL-6 showed a marginal but insignificant increase ([Figure 3](#fig3){ref-type="fig"}A). The MFI shifts showed similar trend ([Figure 3](#fig3){ref-type="fig"}A). In addition, CD11b^+^ cDC2 DCs also showed a significant increase of IL-27 and IDO1 in NCoR1^DC−/-^ when compared with WT mice, whereas IL-6 and IL-10 exhibited an increasing trend ([Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}E). Surface expression of CD80 was significantly decreased upon NCoR1 loss of function in both CD8^+^ and CD11b^+^ primary cDCs in unstimulated conditions ([Figures 3](#fig3){ref-type="fig"}C and 3D). No significant differences were observed for other co-stimulatory genes CD40, CD86, and MHC-II ([Figures S3](#mmc1){ref-type="supplementary-material"}F and S3G). As we found an increased expression of IL-2 cytokine in DC line, we analyzed it in primary DCs using FACS. We found significantly higher IL-2-positive cells in both cDC1 (CD8^+^) and cDC2 DCs (CD11b^+^) in CpG-challenged NCoR1-ablated condition ([Figure S3](#mmc1){ref-type="supplementary-material"}I).Figure 3Conventional DCs from NCoR1^DC−/-^ Mice Show Increased Tolerogenic Behavior upon ActivationSplenocytes from NCoR1^DC−/-^ and WT mice were treated with and without CpG for 6 h and the impact of NCoR1 ablation on different DC subsets was analyzed by flow cytometry.(A) Scatterplots depicting the percentage positive cells for IL-10, IL-27, IDO1, and IL-6 in primary cDC1 DCs from NCoR1^DC−/-^ and WT mice. Corresponding histogram plots depict the MFI shifts (n = 6).(B) Scatterplots demonstrating the percentage positive cells for IL-10, IL-27, IDO1, and IL-6 in primary cDC2 DCs from NCoR1^DC−/-^ and WT mice (n = 6).(C) and (D) Scatterplot showing the percentage of CD80-positive cells in primary cDC1 and cDC2 DCs respectively from NCoR1^DC−/-^ and WT mice before and after 6 h CpG activation. Representative histograms depict the MFI shift.(E) Experimental outline depicting the method employed to identify the *in vivo* impact of NCoR1 depletion on CD4^+^ T cell polarization in NCoR1^DC−/-^ and WT mice.(F) Dot plots showing the percentage of CD4^+^CD44^+^FoxP3^+^-expressing effector T cells from the draining inguinal lymph nodes of NCoR1^DC−/-^ and WT mice vaccinated with CpG and OVA for 1 month (n = 15).p values are calculated using two-tailed unpaired Student\'s t test; error bars represent SEM. \*p ≤ 0.05, \*\*p ≤ 0.01. See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

OVA Immunization Enhances Tregs Frequency in NCoR1^DC-/-^ Mice {#sec2.4}
--------------------------------------------------------------

To access the *in vivo* impact of NCoR1 deletion in cDCs on Th cell differentiation, we vaccinated NCoR1^DC−/-^ and WT mice with ovalbumin (OVA) and CpG at D0 followed by a booster immunization after 30 days ([Figure 3](#fig3){ref-type="fig"}E). Three days after the booster injection, draining lymph nodes were harvested and restimulated with PMA/ionomycin. CD3^+^CD4^+^CD44^+^ effector Th cells were analyzed to assess the differentiation patterns (IFNγ for Th1, IL-13 for Th2, FoxP3 for Tregs, and IL-17 for Th17). We found significantly higher percentages of FoxP3^+^ cells in NCoR1^DC−/-^ when compared with WT mice ([Figure 3](#fig3){ref-type="fig"}F). On the other side, we did not find any change in the IFNγ-, IL-13-, and IL-17-expressing cells in the analyzed effector Th population ([Figure S3](#mmc1){ref-type="supplementary-material"}H). To further check the OVA-specific T cell responses, we also restimulated lymph node cells with OVA-pulsed DCs for 72 h. We found an increased proliferation of effecter Th cells in both WT and NCoR1^DC−/-^ mice when compared with PBS controls ([Figure S4](#mmc1){ref-type="supplementary-material"}A). At the same time, we found a robust and significantly increased FoxP3^+^ Treg population in CD3^+^CD4^+^CD44^+^ Th cells from NCoR1^DC−/-^ when compared with WT mice ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). These experiments confirmed the development of OVA-specific immune responses in both WT and NCoR1^DC−/-^-immunized animals.

Moreover, we performed ELISA to evaluate OVA-specific antibody titers in immunized NCoR1^DC−/-^ and WT animals to confirm the development of OVA-specific responses. We assayed OVA-specific total IgG and its subtypes IgG1, IgG2a, IgG2b, and IgG3. We found high titers of OVA-specific total IgG in both WT and NCoR1^DC−/-^ animals immunized with OVA + CpG when compared with PBS controls ([Figure S4](#mmc1){ref-type="supplementary-material"}C). We did not observe any significant difference in total IgG levels as well as IgG1, IgG2a, IgG2b, and IgG3 between WT and NCoR1^DC−/-^ mice ([Figure S4](#mmc1){ref-type="supplementary-material"}C).

NCoR1 Loss in cDC1 DCs Enhances Treg Development and Parasite Burden {#sec2.5}
--------------------------------------------------------------------

To explore the *in vivo* implications, we further investigated if NCoR1 KD activated DCs can be adoptively transferred at precise time points to skew T cell polarization into Tregs and the associated disease phenotypes. We employed a well-established helminth infection (*Heligmosomoides polygyrus)* model in C57BL/6 mice ([@bib20]). It is reported that the enhanced Treg population in mesenteric lymph nodes (MLNs) increases worm loads in the intestine ([@bib70]).

Adoptive transfer of CpG-pulsed NCoR1 KD cDC1 DC line at (Day 10) D10 post helminth infection in mice resulted in significantly increased egg counts at D13 and D14 post-infection ([Figure 4](#fig4){ref-type="fig"}A). The excreted egg numbers were found to be consistently higher as measured until D18. In addition, the intestinal worm load was also observed to be significantly higher in NCoR1-depleted cDC1-treated animals ([Figures 4](#fig4){ref-type="fig"}B and [S5](#mmc1){ref-type="supplementary-material"}A). Besides, NCoR1 KD cDC-treated mice depicted a profound increase in FoxP3^+^ effector Th cells in the MLNs when compared with controls ([Figures 4](#fig4){ref-type="fig"}C and [S5](#mmc6){ref-type="supplementary-material"}B). No differences were observed in Tbet^+^ cells, whereas GATA3^+^ cells were also significantly increased ([Figure S5](#mmc1){ref-type="supplementary-material"}C).Figure 4NCoR1 Loss in cDCs Enhances Treg Frequency *In Vivo* Leading to Increased Disease Burden in Mice(A) Line graph demonstrating the egg loads in the feces of *H. polygyrus-*infected C57BL/6J mice at different days post-helminth infection after treatment with CpG-pulsed NCoR1 KD and control CD8α^+^ cDC1 DCs. The eggs were counted until D18 post-infection (n = 8).(B) Bar graph showing the intestinal worm counts from activated NCoR1 KD and control cDC1 DC-treated C57BL/6J mice 15 days post-infection (n = 5).(C) Scatterplot showing the increased effector CD25^+^FoxP3^+^ Treg population in MLN of CpG-pulsed NCoR1 KD DC-treated mice compared with control cell-treated animals.(D) Line graph demonstrating the egg loads in the feces of *H. polygyrus-*infected NCoR1^DC−/-^ and WT C57BL/6J mice at different days post-helminth infection after CpG treatment. The eggs were counted until D17 of infection, and then animals were dissected for intestinal worm counting and T cell profiling from MLNs (n = 5).(E) Bar plot showing the helminth worm counts from the intestines of CpG-treated NCoR1^DC−/-^ and control C57BL/6J mice on D17 post infection (n = 5).(F) Bar graph depicting the effector CD25^+^FoxP3^+^ Treg cells in the MLNs of CpG-treated NCoR1^DC−/-^ and WT mice 17 days post-helminth infection (n = 5).(G) Line graph demonstrating the paw inflammation in *L. major*-infected NCoR1^DC−/-^ and WT mice before and after CpG treatment. The CpG treatment was given on D18 after infection. Five animals were used in each group.(H) Bar plot showing the increase in percentage positive FoxP3 Th cells in draining lymph nodes of NCoR1^DC−/-^ and WT mice at D24 after infection. Five mice were used in each group.p values are calculated using two-tailed unpaired Student\'s t test; error bars represent SEM. \*p ≤ 0.05, \*\*p ≤ 0.01. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

To validate our adoptive transfer observations *in vivo* in NCoR1^DC−/-^ animals, we infected the NCoR1^DC−/-^ and WT mice with helminth larvae and treated the animals with CpG at D10 post-infection. We found a significantly increased helminth egg load at D17 in the feces of NCoR1^DC−/-^ mice compared with WT animals ([Figure 4](#fig4){ref-type="fig"}D). The intestinal worm counts were also increased ([Figure 4](#fig4){ref-type="fig"}E). In addition, the effector CD44^+^ Th cell profiling from MLNs of infected animals showed an increased FoxP3^+^ population in NCoR1-ablated mice ([Figure 4](#fig4){ref-type="fig"}F). We did not find any significant differences in the GATA3 and Tbet-expressing Th cells ([Figure S5](#mmc1){ref-type="supplementary-material"}D). We also developed a *Leishmania major* parasitic infection model. After subcutaneous injection of *parasite* in the right footpad of NCoR1^DC−/-^ and WT mice, paw thickness was monitored before and after CpG challenge. As cross-presenting DCs are essential for developing immune protection against *L. major* between 17 and 19 days ([@bib5]), mice were treated with CpG at day 18 post-infection. We observed a significantly increased (p value ≤ 0.020) foot inflammation at day 21 post infection in NCoR1^DC−/-^ animals when compared with WT mice ([Figure 4](#fig4){ref-type="fig"}G). Although the NCoR1^DC−/-^ mice had thicker paws than the WT mice, the differences disappeared 2 weeks after the CpG injection ([Figure 4](#fig4){ref-type="fig"}G). Draining lymph nodes from NCoR1^DC−/-^ mice also showed significant increase in FoxP3^+^ Th cells ([Figure 4](#fig4){ref-type="fig"}H). These results indicated a strong potential of NCoR1 in inducing Th cell polarization toward Tregs *in vivo* and modulating the underlying disease phenotype. Next, to assess the specificity of antigen presentation of DCs, we injected carboxyfluorescein succinimidyl ester (CFSE) labeled CD45.1^+^ OT-II T cells intravenously in CD45.2^+^ helminth-infected WT and NCoR1^DC−/-^ mice at D12 of infection. Next day, we injected WT DCs pulsed with or without OVA peptide intravenously, and the animals were kept further for 3 days. Then we harvested the splenocytes to check the OVA-specific proliferation of CD45.1-gated cells. We observed no difference in proliferation of CD45.1^+^ OT-II T cells analyzed from WT and NCoR1^DC−/-^ mice suggesting there were similar levels of antigen presentation in both WT and NCoR1^DC−/-^ mice ([Figure S5](#mmc1){ref-type="supplementary-material"}E).

Global Profiling of NCoR1 Identifies Its Direct Control on DC Tolerogenicity {#sec2.6}
----------------------------------------------------------------------------

To characterize the molecular mechanisms underlying NCoR1 depletion mediated tolerogenic behavior in cDC1 DCs, we performed RNA sequencing (RNA-seq) analysis of NCoR1 KD and control cDC1 DC line at 0h and 6h after CpG challenge. Besides, we also performed ChIP-seq profiling of NCoR1 in WT cDC1 DC line in similar conditions. We identified ≈13,000 genomic regions bound by NCoR1 at both 0 and 6 h after CpG activation ([Table S1](#mmc2){ref-type="supplementary-material"}). In addition, we performed ChIP-qPCR for 10 randomly selected NCoR1 peaks to validate the ChIP-seq data ([Figure S6](#mmc1){ref-type="supplementary-material"}A, [Table S1](#mmc2){ref-type="supplementary-material"}). Transcriptome profiling of NCoR1 KD cDC1 line identified 1,099 upregulated in contrast to 537 downregulated genes when compared with control DCs (q-value ≤ 0.05 and 2-fold) ([Figure 5](#fig5){ref-type="fig"}A, [Table S2](#mmc3){ref-type="supplementary-material"}). On the other side, in unstimulated conditions, only 390 and 360 genes were up- and downregulated, respectively, in NCoR1 KD DCs ([Figure 5](#fig5){ref-type="fig"}A, [Table S3](#mmc1){ref-type="supplementary-material"}). Overlap with ChIP-seq data revealed 658 up- and 224 downregulated genes as direct targets of NCoR1 upon CpG activation ([Figure 5](#fig5){ref-type="fig"}A, [Table S2](#mmc1){ref-type="supplementary-material"}). The numbers of NCoR1 directly bound and upregulated genes were much higher than the downregulated genes, confirming NCoR1\'s role as a global transcriptional co-repressor. Pathway enrichment analysis for NCoR1 direct target genes in CpG-activated DCs showed significant enrichment of IL-10 signaling (p value ≤ 10^−7^) and Tregs mediated modulation of APC functions (p value ≤ 10^−6^) ([Figure 5](#fig5){ref-type="fig"}B, [Table S4](#mmc1){ref-type="supplementary-material"}). In contrast, NCoR1-unbound and NCoR1-regulated genes showed pathway enrichments like "Immune response IFN-alpha/beta signaling via MAPKs" and "Cytoskeleton remodeling TGF and WNT and cytoskeletal remodeling" ([Table S5](#mmc6){ref-type="supplementary-material"}). Next, we examined the expression patterns of NCoR1 direct target genes that are differentially regulated in CpG-activated NCoR1 KD cDC1 DCs. Interestingly, cluster 2 revealed a wide variety of tolerogenic genes such as *Lag3, Kmo, Vdr, Cd83,* and *Tgfbr1* along with *Ctla4, Ido1, Ido2, Il-10, Pdl1, and Il-27* ([@bib60]) ([Figure 5](#fig5){ref-type="fig"}C, [Table S2](#mmc3){ref-type="supplementary-material"}). integrative genomics viewer (IGV) snapshots and FPKM (fragment counts/kb/million reads) plots from RNA-seq data showed that these genes are highly upregulated after CpG activation in NCoR1-depleted DCs ([Figures 5](#fig5){ref-type="fig"}D and 5E). This global analysis further confirmed our *in vitro* and *in vivo* observations that NCoR1 KD cDCs develop strong tolerogenic behavior upon activation.Figure 5Global Profiling of NCoR1 in cDC1 DC Line Depicts Its Direct Control on DC Tolerance(A) Scatterplot demonstrating the global RNA-seq data of NCoR1 KD and control CD8α^+^ cDC1 DC line after 6-h CpG challenge. Red and blue dots indicate the significantly up- and downregulated genes, respectively. Genes of interest are marked in bold. The inset bar graph shows the number of genes directly or indirectly controlled by NCoR1 (n = 2), see also [Table S2](#mmc3){ref-type="supplementary-material"}.(B) Top biological pathways significantly enriched for the list of direct target genes identified from RNA-seq analysis of 6 h CpG-activated NCoR1 KD DCs. See also [Table S4](#mmc5){ref-type="supplementary-material"}.(C) Heatmap depicting the clusters observed for the list of genes directly regulated by NCoR1 at 0 h and 6 h after CpG challenge. Important DC immune tolerance genes regulated by NCoR1 are marked in bold. See also [Tables S2](#mmc3){ref-type="supplementary-material"} and [S3](#mmc4){ref-type="supplementary-material"}.(D) IGV snapshots showing the NCoR1 binding and RNA-seq tag density observed at *Il-10, Ahr, Pdl1,* and *Ido2* tolerogenic genes.(E) FPKM (fragment counts/kb/million reads) plots demonstrating the levels of transcript expression for important DC tolerogenicgenes identified to be directly regulated by NCoR1 in CD8α^+^ cDC1 DCs. See also [Table S2](#mmc3){ref-type="supplementary-material"}.

NCoR1 Strongly Represses the PU.1-Bound Enhancers on Tolerogenic Genes {#sec2.7}
----------------------------------------------------------------------

To identify the molecular mechanism underlying NCoR1-mediated DC tolerance, we have performed an integrative genomic analysis. Our *de novo* motif prediction within NCoR1 ChIP-seq peaks identified PU.1 as highly enriched motifs (55%--60% with p value ≤10^−3^) in both unstimulated and CpG-challenged conditions ([Figures 6](#fig6){ref-type="fig"}A and 6B). Furthermore, RUNX1, BATF, and IRF: BATF motifs were enriched in unstimulated DCs, whereas RUNX1, FRA1, NF-κB, ATF7, and PU.1: IRF motifs were enriched in CpG condition ([Figures 6](#fig6){ref-type="fig"}A and 6B). To substantiate our motif predictions, we overlapped NCoR1 binding in cDC1 DC line with publically available TF ChIP-seq data from primary bone marrow-derived dendritic cells (BMDCs) ([@bib22]). We found strong overlap of NCoR1 with PU.1 (50%--55%), NF---kB (35%--38%), IRF1 (20%--25%), IRF4 (19%--23%), Junb (18%--22%), and the active enhancer mark H3K27ac (60%--65%). Moreover, we performed ChIP-seq and ChIP-qPCR for PU.1 in cDC1 DC line to validate our predictions. We found a strong overlap of PU.1 (≥60%) with NCoR1 peaks, confirming it to be the most putative NCoR1-recruiting factor in DCs ([Figures 6](#fig6){ref-type="fig"}C, [S6](#mmc7){ref-type="supplementary-material"}B, and S6C).Figure 6NCoR1 Strongly Represses PU.1-Bound Super-Enhancers Present on Tolerogenic Genes after CpG Activation in CD8α^+^ cDCs(A) Top significantly enriched *de novo* predicted DNA motifs of TFs in NCoR1 ChIP-seq peaks of unstimulated CD8α^+^ cDC1 DC line.(B) Top significantly enriched DNA motifs of TFs in NCoR1 ChIP-seq peaks of 6-h CpG-stimulated CD8α^+^ cDC1 DCs.(C) Bar graph showing the percentage overlap of NCoR1 with PU.1 ChIP-seq peaks before and after 6 h CpG activation.(D) SeqMINER clustering showing clusters I-II depicting increased NCoR1 binding after CpG activation in cDC1 DC line when compared with unstimulated cells. Corresponding PU.1 ChIP-seq data lanes show its overlap with NCoR1-bound regions. Corresponding density plot shows the differential enrichment of reads in CpG compared with unstimulated at clusters I-II genomic regions. See also [Table S6](#mmc7){ref-type="supplementary-material"}.(E) Distribution of PU.1 ChIP-seq signals across the total PU.1-bound regulatory regions in CpG-activated CD8α^+^ DCs. Bound regions were ranked by the tag counts within the PU.1-enriched peaks to identify the super-enhancer regulatory regions or genes. Tolerogenic genes enriched in the PU.1 super-enhancer regions are marked. See also [Table S7](#mmc8){ref-type="supplementary-material"}.(F and G) Distribution of NCoR1 ChIP-seq signals across the total NCoR1-bound regulatory regions in unstimulated and CpG-activated CD8α^+^ DCs. Bound regions were ranked by the tag counts within the NCoR1-enriched peaks to identify the regulatory regions or genes super-repressed by NCoR1. Tolerogenic genes enriched in the NCoR1 super-repressed regions are marked. See also [Table S7](#mmc8){ref-type="supplementary-material"}.(H) Metagene plot showing the RNA Pol-II enrichment in unstimulated and 6-h CpG-stimulated control and NCoR1 KD DCs within the gene-body regions of the genes that are annotated to NCoR1 bound cluster I-II genomic regions.(I) Metagene plot depicting the RNA Pol-II enrichment profile in unstimulated and 6 h CpG-stimulated control and NCoR1 KD DCs within the gene-body regions of the genes that are upregulated in 6 h CpG-activated NCoR1 KD DCs in RNA-seq data.(J) IGV snapshots showing the ChIP-seq enrichments of NCoR1, PU.1, and RNA Pol-II at tolerogenic genes Il-10 and Pdl1 at 0 h and 6 h CpG-stimulated CD8α^+^ cDC1 DC line. RNA-Pol-II enrichment in CpG-activated control and NCoR1 KD DCs demonstrate the real-time transcription of these representative tolerogenic genes. The horizontal bars above the plot show the PU.1-bound super-enhancer (SE) regions that are strongly repressed (SR) by NCoR1 after CpG activation.(K) Representative western blot picture for NF-κB subunits RelA and RelB depicting their nuclear translocation at 0 h, 2 h, and 6 h after CpG activation in control and NCoR1 KD CD8α^+^ cDC1 line. Corresponding densitometric analysis bar plots shows the relative intensity of RelA and RelB from four biological replicates (n = 4).(L) Electrophoretic mobility shift assay (EMSA) demonstrating the binding activity of RelA and RelB at 0 h, 2 h, and 6 h after CpG activation. RelA and RelB bands are indicated by the marks.(M) Fragment counts/kb/million read counts plots from control and NCoR1 KD RNA-seq data showing the differential expression of NF-κB negative regulators of NF-κB canonical signaling.(N) RelA ChIP-qPCR depicting the enrichment of RelA at 10 randomly selected genomic regions when compared with negative control genomic regions.p values are calculated using two-tailed paired Student\'s t test; fold change error is depicted as SEM. \*p ≤ 0.05. See also [Figures S6](#mmc1){ref-type="supplementary-material"} and [S7](#mmc1){ref-type="supplementary-material"}.

To identify the mechanistic control of gene regulation by NCoR1, we did SeqMINER ([@bib81]) clustering to identify the regulatory regions differentially bound by NCoR1 in CpG-activated cDCs compared with unstimulated conditions ([Figure S6](#mmc1){ref-type="supplementary-material"}B). Two of these genomic clusters (clusters I-II) showed increased NCoR1 binding, whereas clusters III-XI showed similar enrichment after activation ([Figures 6](#fig6){ref-type="fig"}D and [S7](#mmc8){ref-type="supplementary-material"}A). Interestingly, these regions were annotated to 214 genes that were significantly upregulated in NCoR1 KD DCs upon CpG activation, which includes major tolerogenic genes *Il-10, Pdl1, Ido2, Vdr,* and *Cd83* ([Table S6](#mmc7){ref-type="supplementary-material"}). The cluster I-II genomic regions were also enriched for TFs PU.1, IRF1, IRF4, Junb, and H3K27ac marks, whereas RelA and RelB were enriched only after activation ([Figure S6](#mmc1){ref-type="supplementary-material"}B). Thus, these regulatory regions appear to be the hotspots where several of these activating TFs appear to form complexes.

Moreover, to identify if enhancers at tolerogenic genes are strongly repressed by NCoR1 after CpG challenge, we ran the super-enhancer discovery program to rank PU.1- and NCoR1-bound signals ([Table S7](#mmc8){ref-type="supplementary-material"}). We found that PU.1 super-enhancers on tolerance-inducing genes like *Il-10, Pdl1, Cd83, Ctla4*, and *Tgfβr1* were strongly repressed by NCoR1 after CpG activation ([Figures 6](#fig6){ref-type="fig"}E--6G). Our ChIP-qPCR analysis further confirmed the enrichment of PU.1 at these NCoR1-bound genomic regions ([Figure S7](#mmc1){ref-type="supplementary-material"}B). This suggested that NCoR1 masks the PU.1-bound enhancers after DC activation to prevent induction of the major tolerogenic genes. We performed RNA Pol-II ChIP-seq and ChIP-qPCR in control and NCoR1 KD cDC line before and after CpG activation to estimate the changes in transcription rate of differentially regulated genes ([Figure S7](#mmc1){ref-type="supplementary-material"}C). We observed profoundly increased gene body RNA Pol-II tag counts for the cluster I-II annotated genes that are upregulated in NCoR1-depleted cDCs ([Figures 6](#fig6){ref-type="fig"}H--6J). The downregulated genes showed a decreased Pol-II tag density ([Figures S7](#mmc1){ref-type="supplementary-material"}C and S7D). Representative IGV snapshots depicted the normalized ChIP-seq and RNA-seq tag counts at major tolerogenic genes *Il-10* and *Pdl1* ([Figure 6](#fig6){ref-type="fig"}J).

Collectively, these results demonstrated that NCoR1 directly represses the tolerogenic enhancers after DC activation. Hence upon NCoR1 depletion, these genes are derepressed leading to their enhanced transcription and concomitant mRNA expression after DC activation. This NCoR1-mediated repression of the tolerogenic program appears to be a very important event to prevent the cDCs from going into tolerogenic modality under the strong inflammatory stimulus.

NCoR1 Depletion Perturbs NF-κB Activity on Tolerogenic Genes {#sec2.8}
------------------------------------------------------------

We found a significant enrichment of NF-κB DNA motif in NCoR1-bound regions, and a fine balance of NF-κB activity controlling the immunogenic versus regulatory phenotype in DCs has been widely reported ([@bib17], [@bib71], [@bib75]). Therefore, two mechanisms could be suggested: (1) NCoR1 directly represses PU.1-regulated tolerogenic genes and (2) it directly represses inhibitors of RelA (NF-κB), which provides for immunogenic functions. Therefore, we probed NF-κB nuclear translocation (RelA and RelB) and binding activity in NCoR1 KD and control cDC1 DCs before and after CpG activation. We found significantly inhibited RelA translocation and activity in NCoR1-depleted DCs at 2 h after activation, whereas RelB activity was unaffected ([Figures 6](#fig6){ref-type="fig"}K and 6L). We found increased RelA nuclear localization and binding at 2 h when compared with 6 h, whereas RelB comes up at 6 h after CpG activation. Interestingly, NCoR1 had little, if any, impact on RelB activity, which is known for immune tolerance in DCs. In addition, we also observed significantly increased expression of negative regulators of NF-κB signaling, i.e., *Tnfaip3*, Nfkbia, and *Traf1* along with cytokine-signaling regulators *Socs1* and *Socs3* in NCoR1 KD DCs ([Figure 6](#fig6){ref-type="fig"}M). RelA ChIP-qPCR further confirmed an overall decreased RelA enrichment on selected tolerogenic/immunogenic genes except Il-10 and Il-23a in activated NCoR1-depleted DCs ([Figure 6](#fig6){ref-type="fig"}N). This indicated toward a role of NCoR1 in perturbing NF-κB activity to fine-tune DCs immunogenic versus tolerogenic state.

Discussion {#sec3}
==========

DCs link innate to adaptive immunity and regulate a fine balance of inflammatory and tolerogenic responses to prevent immune pathology. Although the signaling pathways underlying immunogenic and tolerogenic program are explored, the mechanisms underlying fine control of this balance in DCs is of paramount interest for therapeutic approaches and are largely unknown. Using *in vitro, ex vivo,* and *in vivo* models, we revealed that NCoR1 is a master repressor of the tolerogenic program in cDC1 DCs and its depletion renders DCs tolerogenic, irrespective of activation by any strong TLR ligand or microbe. NCoR1-depleted DCs have strong potential to polarize Th cells into Tregs *ex vivo* and *in vivo* with a concomitant increase in disease phenotype*.* Moreover, we demonstrated using integrative genomic analyses that NCoR1 strongly represses tolerogenic genes and its KD modulates NF-κB activity in activated DCs that could shift immunogenic program toward tolerance.

A number of reports suggested that treatment of DCs with a variety of strong NR ligands such as vitamin-D and dexamethasone induces DC tolerance by suppressing their activation along with an increased IL-10 production ([@bib4]). NRs are well known to control their target genes by switching from co-repressor to co-activator complexes upon stimulation ([@bib43], [@bib47]). Recently, NCoR1 co-repressor has been reported to interact with non-NR TFs such as NF-κB and AP1 that are crucial for DC function ([@bib10], [@bib27], [@bib36]). Activation signals remove NCoR1 from co-repressor complex through recruitment of activating TFs like NF-κB or through complex destabilization by kinases such as p38 and pErk ([@bib23]). In DCs CpG stimulation activates canonical NF-κB signaling along with phosphorylation of p38 and Erk kinases ([@bib51], [@bib86]). Activation of Erk kinase is predominantly reported to induce IL-10 expression, whereas p38 largely induces inflammatory cytokines like IL-12 ([@bib59], [@bib86]). We found a profoundly increased pErk activity and concomitantly increased IL-10 levels in activated NCoR1 KD DCs. At the same time PDL1, IL-27, and IDO1 genes were upregulated, which are also reported to induce strong tolerogenic responses ([@bib57], [@bib65], [@bib68], [@bib83]). The IL-10 cytokine further induces *Pdl1* through STAT3 signaling ([@bib78]). The expression of major tolerogenic genes like Ido1, Pdl1, and Il-10 are also induced by IL-27 cytokine, an IL-12 family member cytokine through STAT1 and STAT3 signaling ([@bib12], [@bib48]). Both these STATs were increased in NCoR1 KD DCs ([@bib12]), which are known to induce regulatory Tr1 cells by inhibiting Th17 cell development ([@bib34]). The increased IL-2 could also enhance the secretion of IL-27-induced IL-10 ([@bib48]). Studies suggest that STAT3 is also phosphorylated via both IL-6 and IL-10 signaling in immune cells ([@bib50]). It is unlikely that increased IL-6 is responsible for this STAT3 activation in NCoR1 KD cells as the *IL-6rα* expression was significantly decreased after CpG stimulation. There is a concomitant increase in *Socs3* as well, which strongly inhibits STAT3 phosphorylation leaving open the IL-10 signaling pathway ([@bib2]). Socs2 and Socs3 are also reported to suppress uncontrolled inflammatory cytokine expression and were highly elevated in tolerogenic-state mature DCs ([@bib15], [@bib84]).

Contrary to the reported suppression of IL-12 by enhanced IL-10 signaling in DCs ([@bib39]), we noticed a marginal increase of IL-12 in NCoR1 KD DCs when compared with the robust increase of IL-10 production. Last but not the least, IL-12p40 homo-dimers are inhibitory and IL-12p70 is not significantly upregulated in NCoR1 KD DCs. Type-I IFN signaling is also suggested to stimulate IL-10 and suppress IL-12 and IL-23 cytokines in DCs ([@bib82]). Interestingly, we found *Ifnβ1* and its signaling intermediate *Stat2* significantly increased in CpG-stimulated NCoR1 KD DCs. IFNβ1 is also known to represses IL-12 expression ([@bib87]).

Some of the surface markers and secreted factors that showed a marginal increase after NCoR1 KD are often considered inflammatory. Nevertheless, co-stimulation and antigen presentation by MHC class-II are required for Treg generation ([@bib54]). Therefore, an increase of co-stimulatory molecules can also contribute to Treg differentiation. As Tregs express CD25 (IL-2Rα), increased IL-2 secreted by NCoR1 KD DCs could induce Treg proliferation and clonal expansion and further contribute to tolerogenicity. In RNA-seq, we find upregulation of IL-12p35 and this molecule has inflammatory (IL-12p70) as well as anti-inflammatory/tolerogenic properties (IL-35 composed of IL-12p35 and EBI3) ([@bib14]).

Furthermore, we characterized the direct and indirect target genes of NCoR1 for mechanistic insight. We found a strong overlap of PU.1 binding with NCoR1, suggesting it as the most putative TF-tethering NCoR1 in DCs. Integrative genomics demonstrated that NCoR1 masks the PU.1-bound super-enhancers at the major tolerogenic genes including *Il-10, Cd83, Ctla4,* and *Pdl1.* Therefore, upon NCoR1 depletion these genes are derepressed leading to enhanced transcription as evident by increased gene body RNA Pol-II counts after activation. We also observed a significant enrichment of NF-κB at NCoR1 peaks in CpG-activated condition, which suggested involvement of NF-κB TF in NCoR1-mediated effects. Recent reports also indicated that perturbations in the activity of different NF-κB subunits like RelA and RelB modulate DCs\' inflammatory versus tolerogenic phenotype ([@bib6]). We identified that RelA-binding activity was profoundly reduced after activation, whereas RelB was unaffected. In addition, NCoR1 directly represses negative regulators of canonical NF-κB signaling such as Tnfaip3 (A20), Traf1, and Pias1, which are well reported to repress inflammatory responses by inhibiting RelA activity ([@bib32], [@bib37], [@bib63], [@bib76]). We also noticed increased RelB translocation and activity from 2 to 6 h after CpG activation in CD8α^+^ cDCs, whereas the RelA activity was reduced. It would be further interesting to characterize how this switch of NF-κB activity regulates DC responses. In addition, we showed that increased NCoR1 biding after CpG activation overlaps with binding of other activating TFs. Therefore, it is highly probable that other activating TFs may also bind at these tolerogenic enhancers after NCoR1 depletion. Treatment with live bacteria showed even more pronounced tolerogenic effects compared with CpG challenge, which suggests that multiple strong stimulations further enhance tolerogenicity in NCoR1 KD DCs. Altogether, our integrative genomic analysis identified NCoR1 as a master regulator of the tolerogenic program in DCs.

Limitations of the Study {#sec3.1}
------------------------

In this study we have majorly used cDC1 mutuDC line and validated the findings *ex vivo and in vivo* using primary DCs. It is important to mention that from a single WT C57BL/6 mice one can get nearly 100,000 cDC1 DCs in good condition from splenocytes, using magnetic bead-based kits. Therefore, using primary DCs is a major limitation for high-throughput genomic analysis such as ChIP-seq and bulk RNA-seq that we reported here.

Methods {#appsec3}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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